Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Guns For Top-Three Pharmaceutical Seat In China

This article was originally published in PharmAsia News

Executive Summary

Greater China has been the fastest-growing region for Bayer HealthCare; its pharmaceutical business there increased 30 percent to achieve revenue of €1.8 billion in 2007 ($2.8 billion). The company attributes the success to its focus on OTC business. Generics, especially OTC drugs, will form the core of Bayer's growth in China after 2008 and it aims to be among the top three health care MNCs. However, some gaps need plugging: the firm has yet to launch in the country its top three blockbuster drugs, namely, Betaferon (interferon beta-1b), Yasmin (drospirenone/ethinyl estradiol) and Kogenate (recombinant clotting factor VIII). Bayer Schering Pharma plans to launch all its global heavyweights in China within three years and introduce over 20 new products within five years. (Click here for more - Chinese Language)

You may also be interested in...



Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

French Agency Sets Up New Body To Advise On Biosimilar Substitution

The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.

New EU Regulation Extending IVD Deadlines Expected In April

IVD manufacturers look set to be granted up to 18 more months to comply with the EU IVD Regulation very soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel